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SUMMARY
Nitric oxide (NO) plays an important role in the cytotoxic mechanisms responsible for acute renal allograft rejection, where
macrophages produce high levels of inducible nitric oxide synthase (iNOS). By contrast, both the source and the role of NO in chronic
allograft nephropathy (CAN) are still unclear. In this study, the expression of iNOS mRNA and protein was assessed in the kidneys of
patients with graft failure due to chronic rejection. As controls, kidney specimens were obtained from patients undergoing nephrectomies
for primary renal tumours, and from patients suffering from IgA nephropathy or mesangial-proliferative glomerulonephritis. In normal
kidneys, iNOS production was absent or limited to a low signal, while it was found only in the inflammatory infiltrate of kidneys affected
by glomerulonephritis, as assessed by immunohistochemistry and in situ hybridization. In contrast, in CAN, iNOS protein was localized
not only in inflammatory cells, but also in vascular, glomerular, and, more rarely, tubular structures. Accordingly, in situ hybridization
localized iNOS mRNA in both macrophages and lymphocytes, as well as in vascular structures and glomeruli. Double immunostaining
for iNOS and á-smooth muscle actin (á-SMA) or von Willebrand factor (vWf) revealed that smooth muscle cells were the main vascular
source of iNOS, while both mesangial and inflammatory cells were immunostained at the glomerular level. These data demonstrate that
macrophages and lymphocytes are not the only source of iNOS mRNA and protein in human CAN. Vascular smooth muscle and
mesangial cells also synthesize iNOS, raising the question of heterogeneous regulation and function of iNOS in this disease. Copyright
? 1999 John Wiley & Sons, Ltd.
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Despite the increased success of allograft transplan-
tation, the rate of long-term graft attrition has remained
constant, with the half-life of a renal transplant being 7
years or more.1 The leading cause of late kidney allo-
graft failure is chronic rejection.2 Although a role for
both immunological and non-immunological factors has
been suggested,3 neither the aetiology nor the patho-
physiology of this phenomenon is fully understood.
Several reports have hypothesized a role for nitric oxide
(NO) as a pro-inflammatory molecule in various models
of transplant rejection.4–6 Indeed, NO is a highly
reactive radical produced by several cell types which is
involved in different physiological processes,7 as well as
in different diseases.4 NO is derived from the conversion
of -arginine to -citrulline under the activity of the
enzyme nitric oxide synthase (NOS). There are three
major isoforms of NOS:7 the neuronal form (nNOS); the
endothelial form (eNOS), which produces the amounts
of NO required for physiological functions; and the
cytokine-inducible form (iNOS). iNOS is induced by
a number of immunological stimuli, such as IFN-ã,
TNF-á, and LPS, and catalyses a high output of NO,CCC 0022–3417/99/030345–06 $17.50
Copyright ? 1999 John Wiley & Sons, Ltd.which can be cytotoxic. Recent reports have focused
their attention on the role of iNOS in various models
of acute allograft rejection;8 specific iNOS inhibitors
ameliorate the clinical symptoms of acute rejection,9
preventing the cytotoxic effects exerted by macrophage
and lymphocyte-derived iNOS. However, given that the
kidney is a very important source of iNOS at the level of
both epithelial and vascular structures,7 in this study we
have investigated mRNA and protein iNOS expression
and localization in chronic allograft nephropathy
(CAN).MATERIALS AND METHODS*Correspondence to: Cinzia Pupilli, MD, PhD, Dipartimento di
Fisiopatologia Clinica, Unità di Endocrinologia, Università di
Firenze, Viale Pieraccini 6, 50139 Firenze, Italy. E-mail:
c.pupilli@dfc.unifi.itTissues
Renal tissue specimens were analysed from six
patients (one male and five female, age range 21–59
years) who underwent nephrectomy for chronic trans-
plant failure. All routine slides were examined and
histologically scored according to the Banff classification
criteria (three patients were graded as cg3, ct3, ci3, cv3;
two as cg3, ct2, ci3, cv3; and one as cg3, ct2, ci3, cv2).10
A clinical diagnosis of chronic rejection was supported
by the evidence of elevated serum creatinine, protein-
uria, and hypertension. The possibility of recurrent
disease was excluded. All of the patients were on chronicReceived 18 November 1997
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347iNOS IN HUMAN CHRONIC ALLOGRAFT NEPHROPATHYdialysis for chronic renal allograft rejection and during
this period were treated with 1 mg/kg cyclosporin A
(CsA) and 4 mg of methylprednisolone; therapy was
stopped immediately before nephrectomy, performed
because of the occurrence of a slight degree of fever
without sepsis, hypertension, and the need to stop
the immunosuppressive therapy in order to prepare
the patient for a second transplantation. Control tis-
sues included (i) normal renal tissue obtained from
five patients (two male and three female, age range
19–61 years) who underwent nephrectomy because of
localized tumours and (ii) six renal biopsy specimens
obtained from patients (two male and four female,
age range 20–55 years) affected by IgA nephropathy or
mesangial-proliferative glomerulonephritis. Formalin-
fixed, paraffin-embedded, and frozen tissue specimens
were available for both chronic allograft nephropathy
cases and controls. Frozen CAN specimens were com-
pared with frozen controls and paraffin CAN specimens
with paraffin controls. The procedures followed in the
study were in accordance with the ethical standards of
the regional committee on human experimentation.
Antibodies
Anti-iNOS rabbit polyclonal antibody and its control
blocking peptide were purchased from BIOMOL
Research Laboratories, Inc. (DBA, Milan, Italy). The
anti-iNOS antibody was directed against macrophage
NOS c-terminal peptide (1131–1144) and reacted with
iNOS protein in humans and mice.11 In order to identify
smooth muscle cells and endothelial cells, a mouse
monoclonal anti-human á-smooth muscle actin anti-
body (á-SMA; Sigma Immunochemicals, Milan, Italy)
and a rabbit anti-human von Willebrand factor (vWf;
DAKO, Denmark) were used, respectively.
Immunohistochemistry
Paraffin-embedded (7 ìm) or frozen sections (10 ìm)
were cut. Frozen sections were fixed in 4 per cent
paraformaldehyde and both types of sections were sub-
sequently exposed to 3 per cent hydrogen peroxide–
methanol solution to quench endogenous peroxidase
activity. After a 30 min preincubation with normal goat
serum (Vectastain Elite ABC kit; Vector Laboratories
DBA, Milan, Italy), sections were layered for 30 min
with anti-iNOS rabbit polyclonal antibody (1:1200),
followed by biotinylated anti-rabbit IgG antibody andCopyright ? 1999 John Wiley & Sons, Ltd.the avidin–biotin–peroxidase complex.12 3-Amino-9-
ethylcarbazole (AEC; Sigma) was used as a peroxidase
substrate. Sections were then counterstained with Gill’s
haematoxylin and mounted with Kaiser’s glycerol gela-
tin (Merck, Germany). As negative controls, primary
antibodies were omitted or replaced with rabbit serum
or mouse ascites fluid. Furthermore, preadsorption
using iNOS synthetic peptides completely abolished the
staining.
Double label immunohistochemistry
iNOS and vWf or iNOS and á-SMA were co-localized
on the same sections by double label immunohistochem-
istry, according to the method reported in ref. 12.
Briefly, anti-iNOS antibody was applied first and AEC
(red colour) was used as a peroxidase substrate. Sections
were subsequently exposed to anti-vWf or anti-á-SMA
antibodies and Vector SG (bluish-grey colour) was used
as a chromogen. No counterstain was applied.
In situ hybridization
In situ hybridization was performed according to a
technique described elsewhere.13 Briefly, 10 ìm frozen
sections were cut and fixed in 4 per cent paraformalde-
hyde. After a pre-hybridizaton treatment, sections were
dehydrated and 30 ìl of hybridization solution contain-
ing 8#105 counts/min of 35S-labelled human iNOS
RNA probe was applied. Human inducible hepatocyte
NOS RNA probes14 were synthesized from a 2·1 kb
fragment of hep-NOS cDNA cloned into the EcoRI/
BamHI site of pBluescript SK- (Stratagene). cDNA was
digested with EcoRI and BamHI restriction enzymes to
obtain a 2·1 kb cDNA that was subcloned in PGEM-1
plasmid vector. Thereafter, sense and antisense RNA
radiolabelled probes were synthesized using SP6 or T7
RNA polymerases as appropriate (Riboprobe Gemini
System, Promega, Madison, WI, U.S.A.), in the pres-
ence of á-35S-thioUTP (1300 mCi/mmol; NEN-Du Pont,
Paris, France). Hybridization was carried out at 52)C
for 16 h. After that, sections were washed and auto-
radiography was performed.13 The exposure time
varied from 15 to 20 days. Sections were developed
in D19, fixed in Kodak fixative, counterstained
with haematoxylin–eosin–phloxine and mounted with
Permount. Negative controls consisted of sections
hybridized to a sense RNA probe.Fig. 1—Detection by immunohistochemistry of iNOS protein (red colour) in the kidney from a patient with CAN. (A) Absence of iNOS
immunostaining in the normal kidney from a patient who underwent nephrectomy for a localized renal tumour (G=glomerulus; V=vessel). (b) High
levels of iNOS expression in the kidney of a patient affected by CAN. The smooth muscle layer of a large vessel (large arrow), some inflammatory
cells (arrow-heads), and tubular structures (thin arrows) appear intensely positive. (C) High magnification of a vascular wall. Smooth muscle cells
in the media and hyperplastic intima show intense iNOS immunostaining. Some endothelial cells are also positively stained (arrow). (D) High
magnification of infiltrating inflammatory cells. (E) Vasa recta bundles showing immunoreactivity for iNOS. The image does not allow us to
distinguish between smooth muscle, inflammatory, and endothelial cells. (F) Double label immunostaining for iNOS (red colour) and á-SMA (black
colour). iNOS signal is localized over vascular cells showing á-SMA immunopositivity and over inflammatory interstitial cells. (G) Glomerular cells
showing mesangial morphology (arrow-head) exhibit iNOS immunostaining. Immunoreactivity is also present in endothelial (arrows) and
inflammatory cells. (H) Negative control: preadsorption using iNOS synthetic peptides completely abolished the staining in a section adjacent to E.
(A, B) #100, reduced to 67 per cent in printing; (C, E, F, H) #250, reduced to 67 per cent in printing; (G) #400, reduced to 67 per cent in printing;
(D) #1000, reduced to 67 per cent in printingJ. Pathol. 187: 345–350 (1999)
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immunohistochemistry
In situ hybridization for iNOS was performed as
described above. After hybridization, sections were
washed and immunostained for á-SMA or vWf, using
AEC as a peroxidase substrate, and then autoradiogra-
phy was performed. Sections were counterstained with
Mayer’s haematoxylin and mounted with Kaiser’s
glycerol gelatin.
RESULTS
Localization of iNOS protein in human CAN
In normal kidneys, iNOS was virtually undetectable
by immunohistochemistry (Fig. 1A), while glomerulone-
phritis (GN) inflammatory cells were iNOS-positive
(data not shown). In CAN, high immunoreactivity for
iNOS was present not only in mononuclear leukocytes,
but also in vascular structures (Fig. 1B and 1D). Inter-
estingly, vascular positivity had a focal distribution and
was often restricted to part of the media and neointima
(Fig. 1C). In three out of six patients with CAN,
endothelial cells from a few vessels and some glomeruli
also stained positive for iNOS (Fig. 1C). Strong immu-
noreactivity was present over vasa recta bundles, but the
nature of the cells staining positive for iNOS was
uncertain (Fig. 1E). Double immunostaining for iNOS
and á-SMA showed that smooth muscle cells were
an important source of iNOS in addition to vessel-
surrounding inflammatory cells (Fig. 1F). By contrast,
iNOS protein co-localized with vWf in only a few cases.
Several glomerular cells showing mesangial mor-
phology exhibited iNOS immunoreactivity (Fig. 1G), as
confirmed by double label immunohistochemistry for
iNOS and á-SMA. Occasionally, proximal and distal
tubules together with medullary collecting ducts also
showed iNOS reactivity (Fig. 1B). Preadsorption with
a synthetic peptide corresponding to the peptide used
as an immunogen completely abolished the staining
(Fig. 1H).
Localization of iNOS mRNA in human CAN
A weak positive signal for iNOS mRNA was found
over tubular, glomerular, and vascular structures in
normal kidneys (Fig. 2A) and in the kidneys of patients
suffering from GN, where infiltrating mononuclear cells
exhibited a specific hybridization signal (data not
shown). CAN specimens consistently showed iNOS
mRNA expression over vascular structures, glomeruli,
and the interstitium (Fig. 2B), while in sections hybrid-
ized with a sense RNA probe only a few scattered silver
grains were observed (Fig. 2C). In CAN, the majority of
positive cells were identifiable as infiltrating mono-
nuclear cells (Fig. 2B and 2F), which often surrounded
vasa recta bundles. In large and medium-sized vessels,
inflammatory cells could easily be distinguished from
smooth muscle cells (Fig. 2D), while in small vessels this
distinction was less clear. A higher number of glomeruli
showed intense signal all over the tuft, but discrimin-Copyright ? 1999 John Wiley & Sons, Ltd.ation between infiltrating and glomerular cells was also
impossible. To overcome this problem, both in situ
hybridization for iNOS and immunohistochemistry for
á-SMA or vWf were performed on the same section.
Glomerular cells showing mesangial morphology and
á-SMA positivity exhibited high levels of iNOS mRNA
production (Fig. 2E). An intense mRNA signal over
vascular cells showing á-SMA positivity and smooth
muscle morphology was also observed, while iNOS
mRNA rarely co-localized with vWf.
DISCUSSION
The results of this study demonstrate that iNOS is
widely expressed in CAN at both the mRNA and
protein level, as expected in the presence of an ongoing
inflammatory reaction. Previous studies have indeed
reported high iNOS production by inflammatory cells
in rat models of acute renal allograft rejection and in
human GN.8,15 Accordingly, large cells showing charac-
teristic macrophage features, as well as other small
mononuclear cells with lymphocyte morphology, stained
positively for iNOS in the kidneys from patients with
CAN. The relevant iNOS expression by mononuclear
inflammatory cells in CAN can likely be explained by
the presence of high levels of IFN-ã, IL-1, and TNF-á in
this condition.16
The most relevant finding emerging from this study,
however, was the demonstration that in CAN, iNOS
distribution extended throughout vascular, glomerular,
and, in some cases, tubular structures. Double staining
experiments showed that apart from inflammatory cells,
smooth muscle cells were the main source of iNOS
expression. The capability of human vascular smooth
muscle, endothelial, tubular, and mesangial cells to
produce large amounts of iNOS has been clearly shown
in several in vitro models.7 To our knowledge, however,
this is the first in vivo study documenting iNOS synthesis
by human vascular smooth muscle and mesangial cells.
The expression of iNOS by different cell types sug-
gests that different mechanisms regulate iNOS activation
in CAN and that immunological stimulation may not be
the only reason for its induction. One possibility is that
iNOS production results from chronic and repeated
endothelial cell damage. Indeed, the expression of iNOS
has been found in arterial smooth muscle in response to
endothelial injury.17 Furthermore, the focal nature of
vascular smooth muscle, mesangial, and tubular staining
supports the possibility that local stimuli might be
responsible for iNOS activation. Likewise, the discrep-
ancy between high numbers of glomeruli showing iNOS
mRNA expression and low numbers of glomeruli stain-
ing positive for the iNOS protein may reflect the possi-
bility that local levels of cytokines do not consistently
reach concentrations sufficient to allow the synthesis of
the protein product, or that different cell subtypes react
in a heterogeneous manner. The reason for the low levels
of iNOS activation in endothelial cells is also unclear. A
possible explanation may be the relevant endothelial
damage, as demonstrated by the lack of vWf reactivity
in many vessels in spite of an extended á-SMA positivityJ. Pathol. 187: 345–350 (1999)
349iNOS IN HUMAN CHRONIC ALLOGRAFT NEPHROPATHYFig. 2—Detection by in situ hybridization of iNOS mRNA in the kidney of a patient suffering from CAN. (A) Dark field of a normal human
kidney hybridized with the iNOS antisense RNA probe. Positive signal (white grains) is weakly present over tubular, vascular, and glomerular
structures (G=glomerulus; V=vessel). (B) Dark field of a tissue specimen of human CAN hybridized with the iNOS antisense RNA probe. A
strong and diffuse signal is present over two glomeruli (G), the wall of a vessel (V), and in many interstitial cells (I). (C) Dark field of a section
adjacent to A, hybridized with a sense RNA probe. (D) High power magnification of a vessel hybridized with iNOS antisense RNA probe (black
grains). Smooth muscle cells and inflammatory cells show positive iNOS signal. (E) Combined in situ hybridization (black grains) for iNOS and
immunohistochemistry for á-SMA (red colour) in a glomerulus from a patient with CAN. Several cells showing mesangial morphology and
á-SMA positivity (red colour, arrow) exhibit strong iNOS mRNA expression (black grains). (F) High levels of iNOS mRNA (black grains) over
infiltrating mononuclear cells. (A, B, C) #100, reduced to 67 per cent in printing; (D, E) #400, reduced to 67 per cent in printing; (F) #1000,
reduced to 67 per cent in printingcaused by fibro-intimal hyperplasia. In addition, it is of
note that all patients examined were treated with low
dose CsA, which has been shown to act as a powerful
inhibitor of iNOS induction in both vascular smooth
muscle18 and mesangial cells.19 Thus, the possibility alsoCopyright ? 1999 John Wiley & Sons, Ltd.exists that, at least in some cases, iNOS expression
is underestimated. Furthermore, in order better to
quantify the effective NO release in CAN patients,
dosage of NO metabolites in peripheral blood could also
be useful.J. Pathol. 187: 345–350 (1999)
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pathophysiological meaning of such widespread iNOS
production in CAN. A recent report has demonstrated
that rat aortic allografts show a significant increase in
both iNOS mRNA and protein, as well as in intimal
thickness.20 The inhibition of NO production with an
iNOS inhibitor increased the intimal thickening, indicat-
ing that NO suppresses the development of allograft
arteriosclerosis. Moreover, CsA inhibited iNOS expres-
sion in aortic allografts, with an increase in intimal
thickening that was completely suppressed by iNOS
gene transfer. All these data support the possibility that
iNOS expression in kidneys of CAN does not simply
reflect a pro-inflammatory and cytotoxic mechanism.
Studies performed in LPS-injected rats have indeed
shown that inhibition of NO leads to an increased
expression of RANTES, a chemokine involved in the
pathogenesis of CAN.16 Moreover, NO inhibits both
TGF-â and collagen synthesis in mesangial cells.21
Finally, NO may have an inhibitory effect on vascular
smooth muscle cell proliferation.22 Thus, it is reasonable
to suggest that iNOS production by vascular smooth
muscle and mesangial cells in the kidneys of patients
with CAN plays an important role in the inhibition of
allograft arteriosclerosis and glomerulosclerosis. How-
ever, in order to substantiate this point, additional
information is required on the regulatory mechanism
underlying the activation of iNOS in different cell types.ACKNOWLEDGEMENTS
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